EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)

Samir Gupta iD, Nimish V Subhedar iD, Jennifer L Bell iD, Ursula Bowler iD, Charlotte Clarke iD, Christina Cole iD, Kerrianne Dempster iD, Clare Edwards iD, David Field iD, Jane Greenaway iD, Elizabeth Hutchison, Nina Jamieson und 21 weitere

Health Technology Assessment · 2026

DOI: 10.3310/gjsg2422 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Health Technology Assessment, 2026. Verfasst von Samir Gupta und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neonatology, Sidra Medicine, Doha, Qatar. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Ibuprofen, Cyclooxygenase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In extremely preterm babies, born before 28 weeks’ gestation, a large (≥ 1.5 mm in diameter) patent ductus arteriosus present beyond 3 days of age is associated with higher mortality and morbidity than infants without a patent ductus arteriosus. The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus arteriosus. Whether selective early treatment of a large patent ductus arteriosus with ibuprofen improves health and developmental outcomes is not known.

Methods

We conducted a multicentre, randomised, double-blind, placebo-controlled trial evaluating early treatment (≤ 72 hours after birth) with ibuprofen for a large patent ductus arteriosus in extremely preterm infants. The primary outcome was a composite of death or moderate or severe bronchopulmonary dysplasia at 36 weeks’ of post menstrual age. The short-term secondary outcomes included complications of prematurity, patent ductus arteriosus closure and side effects of treatment. The main long-term outcome was survival without moderate or severe neurodevelopmental impairment, using parent report or classified by blinded end-point review committee at 24 months of corrected age. Other secondary outcomes included survival without respiratory morbidity and duration of oxygen supplementation. A health economic evaluation was undertaken.

Results

A total of 326 infants were randomised to ibuprofen and 327 to placebo. The primary outcome occurred in 220/318 infants (69.2%) in the ibuprofen group and in 202/318 infants (63.5%) in the placebo group (adjusted risk ratio 1.09, 95% confidence interval 0.98 to 1.20; p = 0.10). A total of 44 of 323 infants (13.6%) in the ibuprofen group and 33 of 321 infants (10.3%) in the placebo group died by 36 weeks of gestation (adjusted risk ratio 1.32, 95% confidence interval 0.92 to 1.90). Two unforeseeable serious adverse events occurred that were possibly related to ibuprofen. At 24 months of corrected age, outcome data were available for 263 and 274 children in the ibuprofen and placebo groups, respectively. Survival without moderate to severe neurodevelopmental impairment in the ibuprofen and placebo groups was 131/248 (53.0%) and 134/259 (51.9%), respectively; adjusted risk ratio 1.01 (95% confidence interval 0.86 to 1.18); p = 0.901. Survival without respiratory morbidity was 66/210 (31.4%) and 74/220 (33.6%), respectively; adjusted risk ratio 0.92 (95% confidence interval 0.70 to 1.20); p = 0.536. Median duration of oxygen supplementation was 76.0 and 78.0 days, respectively.

Conclusion

The risk of death or moderate or severe bronchopulmonary dysplasia at 36 weeks of post menstrual age was not statistically significantly lower for extremely preterm infants randomised to early treatment with ibuprofen compared to placebo. There was no evidence of an improvement in survival without moderate to severe neurodevelopmental impairment or survival without respiratory morbidity at 24 months’ corrected age, after selective early treatment of a large patent ductus arteriosus with ibuprofen in children born extremely preterm. Future work Future work required includes a trial in babies who are clinically symptomatic and fail to close the patent ductus arteriosus beyond 7 days of age; an individual patient data meta-analysis; follow-up of babies in Baby-OSCAR at 8–10 years of age.

Limitations

Open-label therapy was received by 29.8% of infants in the placebo group, potentially increasing the percentage of infants with patent ductus arteriosus closure in this group. The first dose of trial treatment was administered at a median of 61 hours after birth, later than in other trials. Funding This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 11/92/15.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ductus Arteriosus, PatentIbuprofenCyclooxygenase InhibitorsHumansInfant, NewbornFemaleDouble-Blind MethodMaleBronchopulmonary DysplasiaInfantTreatment OutcomeInfant, Extremely PrematureInfant, PrematureGestational Age

Stichwörter der Autor:innen

BRONCHOPULMONARY DYSPLASIACHILDDEATHIBUPROFENINFANTPATENT DUCTUS ARTERIOSUSPRETERM

Substanzen

IbuprofenCyclooxygenase Inhibitors

Autor:innen und Institutionen

  • Division of Neonatology, Sidra Medicine, Doha, Qatar.
  • Department of Engineering, Durham University, Durham, UK.
  • Liverpool Women's NHS Foundation Trust, Liverpool, UK.
  • National Perinatal Epidemiology Unit (NPEU) Clinical Trials Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Department of Population Health Sciences, University of Leicester, George Davies Centre, Leicester, UK.

ORCID-Profile: Samir Gupta, Nimish V Subhedar, Jennifer L Bell, Ursula Bowler, Charlotte Clarke, Christina Cole, Kerrianne Dempster, Clare Edwards, David Field, Jane Greenaway, Samantha Johnson, Wilf Kelsell, Ann Kennedy, Andy King, Marketa Laube, Louise Linsell, David Murray, Heather O'Connor, Chidubem Okeke Ogwulu, Justine Pepperell, Tracy Roberts, Charles Roehr, Kayleigh Stanbury, Julia Sutton, Richard Welsh, Joy Wiles, Jonathan Wyllie, Edmund Juszczak, Pollyanna Hardy

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Gupta, S., Subhedar, N. V., Bell, J. L., Bowler, U., Clarke, C., Cole, C., Dempster, K., Edwards, C., Field, D., Greenaway, J., Hutchison, E., Jamieson, N., Johnson, S., Kelsell, W., Kennedy, A., King, A., Laube, M., Linsell, L., Murray, D., …, & Baby-OSCAR Collaborative Group (2026). Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial). Health Technology Assessment. https://doi.org/10.3310/gjsg2422

Vancouver

Gupta S, Subhedar NV, Bell JL, Bowler U, Clarke C, Cole C, et al. Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial). Health Technology Assessment. 2026. doi:10.3310/gjsg2422

BibTeX
@article{Gupta2026,
  author = {Gupta, Samir and Subhedar, Nimish V and Bell, Jennifer L and Bowler, Ursula and Clarke, Charlotte and Cole, Christina and Dempster, Kerrianne and Edwards, Clare and Field, David and Greenaway, Jane and Hutchison, Elizabeth and Jamieson, Nina and Johnson, Samantha and Kelsell, Wilf and Kennedy, Ann and King, Andy and Laube, Marketa and Linsell, Louise and Murray, David and O'Connor, Heather and Okeke Ogwulu, Chidubem and Pepperell, Justine and Roberts, Tracy and Roehr, Charles and Sinha, Sunil and Stanbury, Kayleigh and Sutton, Julia and Welsh, Richard and Wiles, Joy and Wyllie, Jonathan and Juszczak, Edmund and Hardy, Pollyanna and Baby-OSCAR Collaborative Group, Baby-OSCAR Collaborative Group},
  title = {Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial (Baby-OSCAR trial)},
  journal = {Health Technology Assessment},
  year = {2026},
  doi = {10.3310/gjsg2422}
}
Kostenlos starten →